A significant study published on October 7, 2026, in Neurology, the official medical journal of the American Academy of Neurology,…
Read More
The technology could get those with ALS, Parkinson’s disease and brain injuries talking again
For millions of individuals living with neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, or those suffering from…
Read More
Roche Acquires Global Rights to Alector’s Parkinson’s Disease Candidate AL050 in Landmark $1.27bn Deal
Swiss pharmaceutical giant Roche has secured global rights to Alector’s prominent preclinical Parkinson’s disease candidate, AL050, in a lucrative transaction…
Read More
FDA Approval of Tavapadon (Juvmo) Validates AbbVie’s $8.7bn Cerevel Takeover and Ushers in a New Era for Parkinson’s Treatment
The United States Food and Drug Administration has officially approved tavapadon, a next-generation dopamine-based therapy developed for the management of…
Read More
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
A new paradigm in therapeutic development is emerging as Remepy, a pioneering startup, successfully completed a Phase IIa clinical trial…
Read More
Yale Researchers Identify Key Proteins That Drive the Spread of Parkinson’s Disease Throughout the Brain
In a significant breakthrough for neurobiology, researchers at the Yale School of Medicine have identified two specific membrane proteins that…
Read More
Remepy’s Hybridopa, a Pioneer in AI-Driven Hybrid Drugs, Demonstrates Significant Efficacy in Parkinson’s Phase IIa Trial
San Francisco, CA – May 2026 – Remepy, a burgeoning health technology startup at the vanguard of integrating pharmaceutical and…
Read More
Yale Researchers Identify Key Proteins Responsible for the Spread of Parkinson’s Disease in the Brain
A groundbreaking study led by the Yale School of Medicine has identified two specific membrane proteins that act as a…
Read More
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
A new era in therapeutic innovation is dawning, marked by the successful Phase IIa clinical trial results for Hybridopa, an…
Read More
Tubulin Identified as a Critical Molecular Safeguard Against Neurodegenerative Protein Aggregation in Alzheimer’s and Parkinson’s Diseases
Scientists at the Baylor College of Medicine have announced a landmark discovery in the field of neurobiology, identifying a novel…
Read More
